%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
uuid:cdb9be42-945b-3949-aa77-cce005572238
adobe:docid:indd:24632813-a640-11e5-9294-f7950737992f
xmp.id:44B8389F1A206811822ACC2C51A0854A
proof:pdf
xmp.iid:FCED804118206811822AA19BC9A4BE53
xmp.did:CD910B7D11206811822ABF5917DAB9A5
adobe:docid:indd:24632813-a640-11e5-9294-f7950737992f
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2016-09-26T11:16:22+08:00
2016-09-26T11:16:22+08:00
2016-09-26T11:16:22+08:00
2016-09-26T11:16:22+08:00
Adobe InDesign CS6 (Macintosh)
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[14.1732 14.1732 536.173 761.123]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/TrimBox[14.1732 14.1732 536.173 761.123]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[14.1732 14.1732 536.173 761.123]/Type/Page>>
endobj
26 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
10 0 0 10 466.6732 38.3033 Tm
(293)Tj
0.005 Tc -0.006 Tw -39.55 66.06 Td
[(could not \037nd an)14.9(y other possible causes for )17.5(TMJ)5.1( )]TJ
-0.005 Tc -0.075 Tw 0 -1.15 TD
[(dislocation e)14.7(xcept for OFD. )29.6(W)39.6(ith aging population)-5( )]TJ
T*
[(and increased use of polypharmac)15(y)65(, some of which)-5( )]TJ
0.005 Tc 0.086 Tw T*
[(can )0.5(induce )0.5(OFD, )0.5(there )0.5(is )0.5(lik)9.8(ely )0.6(to )0.5(be )0.5(increased)5( )]TJ
0.121 Tw T*
[(incidence of OFD. It is also common for OFD)5( )]TJ
0.195 Tw T*
[(to be inadequately treated resulting in v)24.9(arious)5( )]TJ
-0.005 Tw T*
(complications.)Tj
0 Tc 0 Tw 5.83 0 0 5.83 130.4827 633.2333 Tm
(1)Tj
10 0 0 10 133.3977 629.9033 Tm
( )Tj
0.005 Tc 0.254 Tw /Span<>> BDC
-6.222 -1.15 Td
( )Tj
EMC
1.2 0 Td
[(As for the pre)24.9(vious complications of )18.1(TMJ)5( )]TJ
0.166 Tw -1.2 -1.15 Td
(from OFD, in 1989, Osborn )Tj
/T1_1 1 Tf
(et al)Tj
/T1_0 1 Tf
[(. reported a)5( )]TJ
0.051 Tw T*
[(patient who de)24.9(v)14.9(eloped se)24.9(v)14.9(ere de)14.9(generati)24.9(v)14.9(e joint)5( )]TJ
0.039 Tw T*
[(disease of both )18.1(TMJ after mandible dyskinesia.)]TJ
0 Tc 0 Tw 5.83 0 0 5.83 264.7582 587.2333 Tm
(2)Tj
10 0 0 10 267.6732 583.9033 Tm
( )Tj
0.005 Tc 0.172 Tw -19.65 -1.15 Td
[(In )0.5(2010, )0.5(Pekkan )]TJ
/T1_1 1 Tf
[(et )0.5(al)]TJ
/T1_0 1 Tf
[(. )0.5(reported )0.5(a )0.5(patient )0.5(with)5( )]TJ
0.017 Tw T*
[(masticatory muscle pain and )18.1(TMJ osteoarthrosis)5( )]TJ
-0.006 Tc -0.075 Tw T*
(due to dyskinesia.)Tj
0 Tc 0 Tw 5.83 0 0 5.83 140.5397 552.7333 Tm
(3)Tj
-0.006 Tc -0.075 Tw 10 0 0 10 143.4199 549.4033 Tm
[( )54.9(Although there has been se)24.9(v)14.9(eral)-6( )]TJ
0.005 Tc 0.067 Tw -7.225 -1.15 Td
[(reports of )18(TMJ dislocation as a complication of)5( )]TJ
0.035 Tw T*
[(oro-f)9.8(acial dystonia after using neuroleptic drugs)5.1( )]TJ
-0.003 Tc -0.075 Tw T*
(such as haloperidol, benztropine and aripirazole)Tj
0.003 Tw 5.83 0 0 5.83 257.4595 518.2333 Tm
(4-6)Tj
0 Tc 0 Tw 10 0 0 10 265.1732 514.9033 Tm
(, )Tj
0.005 Tc -0.075 Tw -19.4 -1.15 Td
[(t)0.5(o)0.6( )0.5(t)0.6(h)0.5(e)0.6( )0.5(b)0.6(e)0.5(s)0.6(t)0.5( )0.6(o)0.5(f)0.5( )0.6(o)0.5(u)0.6(r)0.5( )0.6(k)0.5(n)0.6(o)25.4(w)0.6(l)0.5(e)0.6(d)0.5(g)0.5(e)0.6(,)0.5( )0.6(t)0.5(h)0.6(i)0.5(s)0.6( )0.5(i)0.5(s)0.6( )0.5(t)0.6(h)0.5(e)0.6( )0.5(\037)0.6(r)0.5(s)0.6(t)0.5( )0.5(r)0.6(e)0.6(p)0.5(o)0.5(r)0.6(t)5( )]TJ
0.05 Tw T*
[(of )17.9(TMJ dislocation due to OFD.)5( )]TJ
0.171 Tw /Span<>> BDC
T*
( )Tj
EMC
1.2 0 Td
[(In )0.6(conclusion, )0.5(we )0.5(report )0.5(a )0.6(patient )0.5(who )0.5(had)5( )]TJ
0.177 Tw -1.2 -1.15 Td
[(bilateral anterior )18(TMJ dislocation due to OFD)5( )]TJ
0.03 Tc 0.3 Tw T*
[(follo)25(wing ICH. )18(This case demonstrate that)30( )]TJ
0.027 Tc T*
[(clinicians should try to control OFD more)27( )]TJ
0.004 Tc -0.075 Tw T*
[(aggressi)24.9(v)14.9(ely to pre)24.9(v)14.9(ent serious complication such)4( )]TJ
0.005 Tc 0.032 Tw T*
[(as TMJ )-18(dislocation.)5( )]TJ
/TT0 1 Tf
0 Tc 0 Tw 0 -2.35 TD
(ACKNOWLEDGEMENTS)Tj
/T1_0 1 Tf
-0.005 Tc -0.075 Tw 0 -1.75 TD
[(This w)9.4(ork w)9.4(as supported by the National Research)-5( )]TJ
0.005 Tc -0.042 Tw 0 -1.15 TD
[(F)14.9(oundation of K)35(orea Grant funded by the K)34.9(orean)5( )]TJ
0.05 Tw T*
[(Go)14.9(v)14.9(ernment \(NRF-2015R1A2A2A01004073\).)]TJ
/TT0 1 Tf
0 Tc 0 Tw 0 -2.35 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.005 Tc 0.195 Tw /Span<>> BDC
8.5 0 0 8.5 71.1732 319.4033 Tm
( )Tj
EMC
0.652 0 Td
(1.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(Blanchet PJ, Rompre PH, La)19.8(vigne GJ, Lamarche)5.1( )]TJ
0.021 Tc 0.3 Tw 0 -1.176 TD
[(C. Oral dyskinesia: )55.1(A clinical o)15(v)15(ervie)25(w)65.1(. )]TJ
/T1_1 1 Tf
[(Int J)21( )]TJ
0.005 Tc -0.005 Tw T*
[(Pr)45(osthodont)]TJ
/T1_0 1 Tf
0.05 Tw ( 2005; 18:10-9.)Tj
0.016 Tc 0.3 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
[(2)11(.)]TJ
/Span<>> BDC
0.76 0 Td
( )Tj
EMC
0.706 0 Td
[(Osborne )18(TE, Grace EG, Schw)9.9(artz MK. Se)25(v)15.1(ere)16( )]TJ
0.014 Tc T*
[(de)15.3(generati)25.2(v)15.2(e changes of the temporomandib)20.1(ular)14.1( )]TJ
0.005 Tc 0.056 Tw T*
[(joint secondary to the ef)25(fects of tardi)24.9(v)14.9(e dyskinesia:)5.1( )]TJ
0.158 Tw T*
[(A literature re)24.9(vie)25(w and case report. )]TJ
/T1_1 1 Tf
-0.005 Tw [(Cr)15(anio)]TJ
/T1_0 1 Tf
0.158 Tw [( 1989;)5( )]TJ
-0.005 Tw T*
(7:58-62.)Tj
0.162 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(Pekkan G, Kilicoglu )54.8(A, )54.9(Algin DI. )17.7(T)34.9(reatment of a)5.1( )]TJ
0.108 Tw 0 -1.176 TD
[(tardi)24.9(v)14.9(e dyskinesia patient with temporomandib)19.8(ular)5.1( )]TJ
-0.003 Tc -0.075 Tw 0 -1.176 TD
[(disorder: )55(A case report. )]TJ
/T1_1 1 Tf
[(J Or)44.9(ofac P)79.9(ain)]TJ
/T1_0 1 Tf
( 2010; 24:212-6.)Tj
-0.004 Tc /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
[(4)-9(.)]TJ
/Span<>> BDC
0.76 0 Td
( )Tj
EMC
0.706 0 Td
[(Ibrahim ZY)129.2(, Brooks EF)80.2(. Neuroleptic-induced bilateral)-4( )]TJ
-0.005 Tc T*
[(temporomandib)19.8(ular joint dislocation. )]TJ
/T1_1 1 Tf
[(Am J Psyc)14.9(hiatry)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 21 0 Td
( )Tj
0.005 Tc 0.05 Tw -21 -1.176 Td
(1996; 153:293-4.)Tj
0.191 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(Undt G, )29.5(W)79.8(eichselbraun )54.6(A, )29.5(W)79.8(agner )54.6(A, K)24.9(ermer C,)5( )]TJ
0.181 Tw 0 -1.176 TD
[(Rasse M. Recurrent mandib)19.7(ular dislocation under)5( )]TJ
0.039 Tc 0.3 Tw 0 -1.176 TD
[(neuroleptic drug therap)9.9(y)65.2(, treated by bilateral)39( )]TJ
-0.008 Tc 0.008 Tw T*
[(e)0.6(m)0.5(i)0.6(n)0.6(e)0.5(c)0.6(t)0.5(o)0.6(m)0.6(y)65.4(.)0.6( )]TJ
/T1_1 1 Tf
-0.086 Tw 5.191 0 Td
[(J)0.6( C)0.6(r)15.5(a)0.5(n)0.6(i)0.5(o)0.6(m)0.6(a)0.5(x)0.6(i)0.5(l)0.6(l)0.6(o)0.5(f)0.6(a)0.5(c)0.6( S)0.5(u)0.6(r)37.4(g)]TJ
/T1_0 1 Tf
9.469 0 Td
[( 1)0.5(9)0.6(9)0.5(6)0.6(;)0.6( 2)0.6(4)0.5(:)0.6(1)0.6(8)0.5(4)0.6(-)0.5(8)0.6(.)]TJ
-0.085 Tw /Span<>> BDC
-16.778 -1.176 Td
( )Tj
EMC
0.652 0 Td
[(6)-13(.)]TJ
/Span<>> BDC
0.76 0 Td
( )Tj
EMC
0.706 0 Td
[(So)0.5(lo)0.5(mon)0.5( S, G)0.5(upt)0.5(a)0.5( S)0.5(, Je)0.5(su)0.5(da)0.5(sa)0.5(n J.)0.5( )17.6(T)70.2(e)0.5(mp)0.5(or)0.5(om)0.5(and)0.5(ib)20.2(u)0.5(la)0.5(r)-8( )]TJ
0.005 Tc 0.009 Tw T*
(dislocation due to aripiprazole induced dystonia. )Tj
/T1_1 1 Tf
0 Tc 0 Tw [(B)-5(r )]TJ
0.005 Tc 0.05 Tw T*
(J Clin Pharmacol)Tj
/T1_0 1 Tf
( 2010; 70:914-5.)Tj
ET
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
<>
endobj
20 0 obj
<>
endobj
32 0 obj
<>
endobj
33 0 obj
<>stream
H\j0E
-EZ#
&&-dM=I
/QEs}K5:B\